Assessment of the Duration of Protection in Campylobacter jejuni Experimental Infection in Humans
- 1 April 2010
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 78 (4) , 1750-1759
Abstract
A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and duration of protection. Healthy Campylobacter -seronegative adults received C. jejuni strain 81-176 via oral inoculation of 10 5 , 10 7 , or 10 9 CFU (5 adults/dose), which was followed by clinical and immunological monitoring. Based on dose range clinical outcomes, the 10 9 -CFU dose ( n = 31) was used to assess homologous protection at 28 to 49 days (short-term veterans [STV]; n = 8) or 1 year (long-term veterans [LTV]; n = 7) after primary infection. An illness dose effect was observed for naïve subjects (with lower doses, 40 to 60% of the subjects were ill; with the 10 9 -CFU dose, 92% of the subjects were ill) along with complete protection for the STV group and attenuated illness for the LTV group (57%). Partial resistance to colonization was seen in STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni . This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.Keywords
This publication has 54 references indexed in Scilit:
- The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coliDiagnostic Microbiology and Infectious Disease, 2010
- Case Series Study of Traveler's Diarrhea in U.S. Military Personnel at Incirlik Air Base, TurkeyClinical and Vaccine Immunology, 2008
- Immunogenicity and Protective Efficacy of Recombinant Campylobacter jejuni Flagellum-Secreted Proteins in MiceInfection and Immunity, 2008
- Host-Pathogen Interactions inCampylobacterInfections: the Host PerspectiveClinical Microbiology Reviews, 2008
- Diagnostic Approach to Acute Diarrheal Illness in a Military Population on Training Exercises in Thailand, a Region of Campylobacter HyperendemicityJournal of Clinical Microbiology, 2008
- Structural Characterization of Campylobacter jejuni Lipooligosaccharide Outer Cores Associated with Guillain-Barré and Miller Fisher SyndromesInfection and Immunity, 2007
- Ganglioside Molecular Mimicry and Its Pathological Roles in Guillain-Barré Syndrome and Related DiseasesInfection and Immunity, 2006
- Campylobacter jejuniInduces Maturation and Cytokine Production in Human Dendritic CellsInfection and Immunity, 2006
- Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milkThe Journal of Pediatrics, 1990
- Serologic Study of Two Clusters of Infection Due to Campylobacter jejuniThe Journal of Infectious Diseases, 1983